BioNTech Files SC 13D on Autolus Therapeutics Stake

TL;DR

**BioNTech just filed an SC 13D on Autolus, signaling continued interest in the biotech firm!**

AI Summary

BioNTech SE filed an SC 13D on February 21, 2024, regarding its ownership in Autolus Therapeutics plc. The filing indicates BioNTech SE's continued interest in Autolus Therapeutics, a company focused on biological products. The filing details the class of securities as Ordinary shares, nominal value $0.000042 per share, including those represented by American Depositary Shares, under CUSIP 05280R100.

Why It Matters

This filing signals BioNTech's ongoing strategic involvement with Autolus Therapeutics, potentially impacting future collaborations or investment decisions in the biotech sector.

Risk Assessment

Risk Level: low — An SC 13D filing generally indicates a significant ownership stake but doesn't inherently suggest high risk without further context of the filer's intentions.

Key Numbers

• $0.000042 — Nominal Share Value (Nominal value per ordinary share of Autolus Therapeutics plc)

Key Players & Entities

• BioNTech SE (company) — filer of SC 13D
• Autolus Therapeutics plc (company) — subject company of SC 13D
• Prof. Ugur Sahin, M.D. (person) — contact person for BioNTech SE
• $0.000042 (dollar_amount) — nominal value per ordinary share of Autolus Therapeutics plc
• February 21, 2024 (date) — filing date of SC 13D

FAQ

From the Filing

0001193125-24-041581.txt : 20240221 0001193125-24-041581.hdr.sgml : 20240221 20240221170133 ACCESSION NUMBER: 0001193125-24-041581 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-90550 FILM NUMBER: 24660732 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190847081 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 SC 13D 1 d782522dsc13d.htm SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Autolus Therapeutics plc (Name of Issuer) Ordinary shares, nominal value $0.000042 per share (including ordinary shares represented by American Depositary Shares)** (Title of Class of Securities) 05280R100*** (CUSIP Number) Prof. Ugur Sahin, M.D. An der Goldgrube 12 D-55131 Mainz Germany Tel: +49 6131-9084-0 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 13, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. ** The Reporting Persons own ordinary shares through the Issuer’s American Depositary Shares, each representing one ordinary share. *** The ordinary shares have no CUSIP number. The CUSIP number for the Issuer’s American Depositary Shares, each representing one ordinary share, is 05280R100. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP No. 05280R100 Page 2 of 7  1   NAME OF REPORTING PERSONS  BioNTech SE  2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  (a) ☐  (b) ☐  3  SEC USE ONLY  4  SOURCE OF FUNDS (See Instructions)  OO  5  CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e